Atomi Financial Group Inc. Buys 314 Shares of Insmed Incorporated (NASDAQ:INSM)

Atomi Financial Group Inc. boosted its stake in Insmed Incorporated (NASDAQ:INSM) by 1.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,248 shares of the biopharmaceutical company’s stock after purchasing an additional 314 shares during the period. Atomi Financial Group Inc.’s holdings in Insmed were worth $1,697,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of INSM. Vanguard Group Inc. raised its stake in shares of Insmed by 2.7% during the first quarter. Vanguard Group Inc. now owns 14,509,235 shares of the biopharmaceutical company’s stock valued at $393,636,000 after acquiring an additional 383,714 shares during the last quarter. Darwin Global Management Ltd. bought a new position in shares of Insmed during the second quarter valued at approximately $237,076,000. Principal Financial Group Inc. lifted its stake in Insmed by 15.2% in the second quarter. Principal Financial Group Inc. now owns 1,657,760 shares of the biopharmaceutical company’s stock worth $111,069,000 after acquiring an additional 218,480 shares during the period. Clearbridge Investments LLC lifted its stake in Insmed by 76.8% in the second quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock worth $110,212,000 after acquiring an additional 714,539 shares during the period. Finally, Capital International Investors purchased a new position in Insmed during the 1st quarter valued at $43,973,000.

Insmed Trading Up 1.2 %

Shares of INSM stock opened at $71.37 on Wednesday. The company has a debt-to-equity ratio of 25.05, a current ratio of 2.71 and a quick ratio of 2.53. The company has a market cap of $10.61 billion, a price-to-earnings ratio of -13.65 and a beta of 1.11. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $80.53. The firm has a fifty day moving average price of $73.91 and a 200-day moving average price of $56.05.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The business had revenue of $90.34 million during the quarter, compared to analyst estimates of $87.95 million. During the same period last year, the firm posted ($1.78) EPS. The firm’s quarterly revenue was up 17.0% on a year-over-year basis. As a group, equities analysts predict that Insmed Incorporated will post -5.42 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares in the company, valued at $7,951,559.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at $7,951,559.28. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Michael Alexander Smith sold 27,871 shares of the company’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the transaction, the insider now owns 67,856 shares of the company’s stock, valued at approximately $5,045,093.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 78,882 shares of company stock worth $5,765,446. Company insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on INSM. Evercore ISI boosted their price target on shares of Insmed from $42.00 to $75.00 and gave the company an “outperform” rating in a research report on Friday, June 21st. The Goldman Sachs Group increased their price objective on Insmed from $74.00 to $102.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. TD Cowen increased their price target on shares of Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Morgan Stanley lifted their target price on shares of Insmed from $60.00 to $85.00 and gave the company an “overweight” rating in a report on Friday, July 12th. Finally, JPMorgan Chase & Co. lifted their price objective on Insmed from $72.00 to $74.00 and gave the company an “overweight” rating in a research note on Thursday, October 3rd. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus price target of $81.53.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.